TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20102667
Drug: Propranolol (β-noradrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (β-noradrenergic antagonist)
Study: 16377919
Drug: Nifekalant (NIF)
Normalized name: Nifekalant
DrugBank: Nifekalant (DB16008)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifekalant (NIF) 0.15-0.3 mg/kg
Study: 12822874
Drug: Interferon-alpha2b +
Normalized name: Fibroblast interferon
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-alpha2b + Ribavirin (1000-1200 mg/day for 48 weeks)
Study: 11402829
Drug: Viscoelastics (ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viscoelastics (ophthalmic viscosurgical device, OVD)
Study: 8428323
Drug: estramustine phosphate
Normalized name: Estramustine phosphate
DrugBank: Estramustine phosphate (DB14674)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: estramustine phosphate 600 mg/m2 orally daily for up to 2 years
Study: 8428323
Drug: adjuvant cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: adjuvant cyclophosphamide 1 g/m2 intravenously every 3 weeks for 2 years
Study: 8428323
Drug: no adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: no adjuvant therapy
Study: 2892864
Drug: Famotidine 40
Normalized name: famotidine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 40 mg at 10 PM
Study: 28003041
Drug: Oat consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oat consumption group (50 g/day oats)
Study: 25647729
Drug: Tenofovir 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenofovir 1% gel
Study: 24012319
Drug: Rifaximin 200
Normalized name: rifAXIMin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin 200 mg tablets twice daily
Study: 19061374
Drug: L-Dopa (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Dopa (200 mg)
Study: 17333809
Drug: Doxycycline, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline, 2 x 200 mg/day for 1 week
Study: 17333809
Drug: Praziquantel, single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel, single dose, 40 mg/kg body weight
Study: 17333809
Drug: Oxytetracycline, 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytetracycline, 15 mg in 0.5 mL medium (in vitro)
Study: 17333809
Drug: Extract of
Normalized name: Extract of tomato
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extract of Eucalyptus comaldensis, 50 mg in 0.1 mL medium (in vitro)
Study: 10724022
Drug: pivmecillinam, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: pivmecillinam, 200 mg three times daily for 3 days
Study: 10724022
Drug: cephalexin, 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: cephalexin, 250 mg four times daily for 7 days
Study: 8730167
Drug: Protective Creams
Normalized name: ostomy, skin fillers, protective creams & sprays
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protective Creams (PCs) against 10% sodium lauryl sulfate (SLS)
Study: 8730167
Drug: Protective Creams
Normalized name: ostomy, skin fillers, protective creams & sprays
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protective Creams (PCs) against undiluted toluene (TOL)
Study: 8730167
Drug: Protective Creams
Normalized name: ostomy, skin fillers, protective creams & sprays
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protective Creams (PCs) against 1% sodium hydroxide (NaOH) and 30% lactic acid (LA)
Study: 8730167
Drug: Protective Creams
Normalized name: ostomy, skin fillers, protective creams & sprays
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protective Creams (PCs) against SLS and NaOH
Study: 26596013
Drug: Intratympanic dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intratympanic dexamethasone injection as initial treatment (group A)
Study: 26596013
Drug: Systemic hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic hormone therapy (group B)
Study: 26596013
Drug: Intratympanic dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intratympanic dexamethasone injection as salvage treatment (group C)
Study: 20617919
Drug: Paraffin baths
Normalized name: Paraffin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paraffin baths 80% wax with 20% topical analgesic (PTA)
Study: 10336539
Drug: Morphine (MOR)
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine (MOR) 2.5, 5, and 10 mg/70 kg
Study: 10336539
Drug: Hydromorphone (HM)
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydromorphone (HM) 0.33, 0.65, and 1.3 mg/70 kg
Study: 10336539
Drug: Meperidine (MEP)
DrugBank: Meperidine (DB00454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine (MEP) 17.5, 35, and 70 mg/70 kg
Study: 30058511
Drug: Discontinued antipsychotic
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinued antipsychotic treatment
Study: 30058511
Drug: Continued antipsychotic
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued antipsychotic treatment
Study: 27531506
Drug: Intensified, multifactorial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified, multifactorial treatment (mean treatment duration 7.8 years)
Study: 27531506
Drug: Intensified, multifactorial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified, multifactorial treatment
Study: 24418924
Drug: 2D video
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2D video preparation
Study: 24418924
Drug: 3D video
Normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3D video preparation
Study: 24418924
Drug: Guide preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guide preparation
Study: 15535489
Drug: lignocaine 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: lignocaine 2% (40 mg)
Study: 11674912
Drug: 50% dextrose
Normalized name: DEXTROSE MONOHYDRATE 5000 mg in 100 mL INTRAVENOUS INJECTION, SOLUTION [Alfa Veterinary 50% Dextrose]
DrugBank: D-glucose (DB01914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% dextrose solution
Study: 17077809
Drug: Risperidone 1
Normalized name: risperidone 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 1 mg/day
Study: 17077809
Drug: Risperidone 4
Normalized name: risperidone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 4 mg/day
Study: 7521534
Drug: Risperidone 8
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperidone 8 mg/day
Study: 9477007
Drug: Risperidone 12
Normalized name: risperidone 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 12 mg/day
Study: 7521534
Drug: Haloperidol 10
Normalized name: haloperidol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 10 mg/day
Study: 9477007
Drug: Risperidone (>=
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (>= 4 mg/day)
Study: 9477007
Drug: Risperidone 1
Normalized name: risperidone 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 1 or 4 mg/day
Study: 9477007
Drug: Risperidone (optimal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (optimal dose)
Study: 3363287
Drug: Pirenzepine 100
Normalized name: pirenzepine
DrugBank: Pirenzepine (DB00670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine 100 mg/day for 3 days
Study: 30419120
Drug: Amoxicillin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (3 days, twice daily)
Study: 30419120
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 days, twice daily)
Study: 27848159
Drug: Recent chemotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Recent chemotherapy (Group R)
Study: 27848159
Drug: No recent
Approvals — FDA: no, EMA: no, PMDA: no
Description: No recent chemotherapy (Group O)
Study: 23760292
Drug: Low-sodium/high-potassium diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-sodium/high-potassium diet with furosemide infusion
Study: 18164013
Drug: B1B1/CC genotype
Approvals — FDA: no, EMA: no, PMDA: no
Description: B1B1/CC genotype
Study: 17062300
Drug: Paracetamol tablet
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paracetamol tablet containing sodium bicarbonate (PSC)
Study: 12702521
Drug: Epirubicin-Cyclophosphamide at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin-Cyclophosphamide at intermediate doses (EC)
Study: 12702521
Drug: Epirubicin-Cyclophosphamide at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin-Cyclophosphamide at full doses (HEC)
Study: 1687238
Drug: Mequitazine (MQZ)
Normalized name: mequitazine
DrugBank: Mequitazine (DB01071)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mequitazine (MQZ) 5 mg BID for 7 days
Study: 6364621
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg phenylethylamine in apple juice
Study: 6364621
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg histamine in apple juice
Study: 6364621
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg tyramine in apple juice
Study: 31748594
Drug: Fenofibrate (145
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate (145 mg tablet) administered once daily for 2 months (Mo2)
Study: 31748594
Drug: Fenofibrate (145
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate (145 mg tablet) administered once daily for 4 months (Mo4)
Study: 27913736
Drug: Topical tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical tranexamic acid (1g in 100mL normal saline during sternal closure)
Study: 25958710
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl at 1 mcg/kg/dose
Study: 25958710
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine at 1 mg/kg/dose
Study: 19635277
Drug: Tinzaparin 175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinzaparin 175 IU/kg subcutaneously once daily for 12 weeks
Study: 19635277
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (tinzaparin for >or=5 days plus oral warfarin for >or=12 weeks)
Study: 16631323
Drug: ondansetron 4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron 4.0 mg
Study: 16631323
Drug: ondansetron 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron 1.0 mg
Study: 9778323
Drug: Antiplatelet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet therapy (aspirin and ticlopidine)
Study: 9778323
Drug: Conventional anticoagulation
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional anticoagulation (heparin or oral anticoagulant)
Study: 7527131
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose aprotinin
Study: 27159397
Drug: 15 mcg
Normalized name: DDAVP 15 MCG/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mcg vaccine
Study: 27159397
Drug: 30 mcg
Normalized name: Avonex 30 MCG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mcg vaccine
Study: 27159397
Drug: Both 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both 15 mcg and 30 mcg vaccines
Study: 21551462
Drug: Dabigatran 50
Normalized name: dabigatran 50 mg oral granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran 50 mg
Study: 11104182
Drug: Cognitive preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive preparation prior to video feedback
Study: 11104182
Drug: No cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: No cognitive preparation (Control)
Study: 1364968
Drug: Olimunostim (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olimunostim (7 consecutive daily doses, perorally)
Study: 7372036
Drug: Treatment groups
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment groups (individual-oriented intervention for high-risk subjects and mass health education for the remaining 70%)
Study: 7372036
Drug: Treatment groups
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment groups (high-risk subgroups)
Study: 7372036
Drug: Treatment groups
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment groups (random population)
Study: 7372036
Drug: Treatment groups
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment groups (whole treatment populations)
Study: 22907790
Drug: 240 ml
Normalized name: Iron 5 MG/240 ML Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 ml daily of 100% Concord grape juice
Study: 19893995
Drug: Diphtheria-tetanus-pertussis/Hib Brazilian
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphtheria-tetanus-pertussis/Hib Brazilian combination vaccine
Study: 17300239
Drug: Simplified creams
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simplified creams
Study: 17300239
Drug: Lipid-free gel
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-free gel
Study: 17300239
Drug: Ordinary cream
Normalized name: ordinary salt combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ordinary cream (5% urea)
Study: 17300239
Drug: One of
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One of the simplified creams
Study: 17300239
Drug: All test
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All test preparations
Study: 16624688
Drug: Caffeine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (4 mg/kg intravenously, equivalent to 2 cups of coffee)
Study: 12515871
Drug: ACE-inhibitor infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACE-inhibitor infusion during CPT
Study: 12515871
Drug: ACE-inhibitor infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACE-inhibitor infusion after dipyridamole
Study: 1692687
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg propranolol (beta-blocker)
Study: 7025784
Drug: Imipramine hydrochloride;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine hydrochloride; treatment duration: three-week treatment periods.
Study: 7025784
Drug: Placebo; treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo; treatment duration: three-week treatment periods.
Study: 29354990
Drug: Alliance therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alliance therapy group with scalp acupuncture, music therapy and rehabilitation
Study: 29354990
Drug: Combination group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination group with music therapy and rehabilitation
Study: 25430812
Drug: Pregabalin 75
Normalized name: pregabalin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 75 mg orally twice daily for 2 weeks starting on the day of surgery
Study: 25430812
Drug: Loxoprofen orally
Normalized name: loxoprofen
DrugBank: Loxoprofen (DB09212)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Loxoprofen orally three times daily for 2 weeks starting on the day of surgery
Study: 12553384
Drug: Ropivacaine 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 150 mg diluted in 60 mL NaCl 0.9%
Study: 12553384
Drug: Ropivacaine 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 150 mg diluted in 30 mL NaCl 0.9%
Study: 12553384
Drug: Ropivacaine 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 150 mg diluted in 40 mL NaCl 0.9%
Study: 1491390
Drug: Chloroquine therapy
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine therapy
Study: 31770012
Drug: Control (before
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (before inhalation, T1)
Study: 27058481
Drug: Cognitive behavior-therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior-therapy anxiety-management (work-anxiety coping group, WAG)
Study: 25233569
Drug: Pressure and
Normalized name: Blood Pressure and Pulse Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pressure and topical anesthetic (20% benzocaine)
Study: 25233569
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no concurrent stimulation)
Study: 22234244
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab (IVB) 1.25 mg and intravitreal triamcinolone acetonide (IVT) 2 mg
Study: 15229206
Drug: Drospirenone oral
Normalized name: drospirenone Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drospirenone oral contraceptive (OC)
Study: 9236408
Drug: Thrombomodulin gene
Normalized name: thymomodulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombomodulin gene mutations (GG‐9/‐10AT, G‐33A, C‐133A)
Study: 1338525
Drug: Captopril (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (4 mg/l mixed into the cardioplegic solution)
Study: 3315268
Drug: Sustained-release theophylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release theophylline (mean 11.2 mg/kg per day)
Study: 3315268
Drug: Sustained-release terbutaline
Normalized name: terbutaline Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release terbutaline (mean 0.25 mg/kg per day)
Study: 27282133
Drug: Cinnamaldehyde (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnamaldehyde (20 mg)
Study: 28957728
Drug: Nicotine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (4 mg)
Study: 27282133
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cinnamaldehyde and nicotine
Study: 24419925
Drug: Tamsulosin 0.4
Normalized name: tamsulosin 0.4 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.4 mg and Tadalafil 5 mg
Study: 19083404
Drug: Purple passion
Normalized name: Purple passionflower
DrugBank: Passiflora incarnata flower (DB13974)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purple passion fruit peel extract (150 mg/d)
Study: 10518002
Drug: Plasma homocysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma homocysteine (HC) below 7.5 micromol/l
Study: 10518002
Drug: Plasma vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma vitamin B12 (B12) above 300 pmol/l
Study: 1646066
Drug: Prior locoregional
Normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior locoregional radiation therapy
Study: 30450601
Drug: Control (buffer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (buffer solution)
Study: 21291031
Drug: Sublingual ketorolac
Normalized name: ketorolac Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual ketorolac (30 mg/1 mL) and mepivacaine paracervical block
Study: 21291031
Drug: Mepivacaine-only paracervical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepivacaine-only paracervical injection (standard group)
Study: 10023614
Drug: Intensive outpatient
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive outpatient or short-term residential treatment
Study: 26799632
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg BI 135585 (single dose)
Study: 26799632
Drug: 5-200 mg
Normalized name: hydrocodone
DrugBank: Hydrocodone (DB00956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-200 mg BI 135585 (multiple doses)
Study: 22722509
Drug: Agomelatine (AGO)
DrugBank: Agomelatine (DB06594)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Agomelatine (AGO) 25-50 mg/d
Study: 22722509
Drug: Venlafaxine XR
Normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Venlafaxine XR (VLX) 75-150 mg/d
Study: 17598865
Drug: Twice-weekly PUVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly PUVA
Study: 17598865
Drug: Thrice-weekly PUVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice-weekly PUVA
Study: 12236845
Drug: Enteric coated
Normalized name: Mesasal Enteric Coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric coated beads (1 x 200 mg)
Study: 12236845
Drug: Enteric coated
Normalized name: Mesasal Enteric Coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric coated mini-tablets (4 x 50 mg)
Study: 12236845
Drug: Buffered tablet
Normalized name: CVS Aspirin 325mg Buffered Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buffered tablet (2 x 100 mg)
Study: 11341606
Drug: Cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 400 mg bd for five days presurgery
Study: 7488278
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg cM-T412
Study: 2302375
Drug: Midazolam and
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam and fentanyl combination
Study: 6326562
Drug: Guar gum
Normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guar gum (15 g/day)
Study: 7435246
Drug: Placebo or
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo or no medication
Study: 26298832
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of vaporized cannabis (22 mg THC)
Study: 26298832
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of vaporized cannabis (5.5 mg THC)
Study: 12618744
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (ICS) as initial long-term control therapy
Study: 11112027
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy (tacrolimus/corticosteroids)
Study: 11112027
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (tacrolimus/corticosteroids/azathioprine)
Study: 8323890
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg plain bupivacaine (isobaric group)
Study: 8323890
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg hyperbaric bupivacaine (hyperbaric group)